Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2024-04-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 海思科医药集团股份有限公司 regarding the temporary use of idle raised funds to supplement working capital. It details the approval by the board and supervisory committee, references regulatory guidelines on the management and use of raised funds, and provides specifics on the amount, purpose, and duration of the fund usage. The document does not contain financial statements or detailed financial performance data but is a formal disclosure about the company's capital management activities related to raised funds. It is not an annual report, interim report, or earnings release. It is not a proxy, voting result, or management change announcement. The document fits the category of Capital/Financing Update (CAP) as it concerns the use and management of capital raised through a non-public stock issuance and the temporary allocation of those funds for liquidity purposes.
2024-04-19 Chinese
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2023 Annual General Meeting (AGM) of the company 海思科医药集团股份有限公司. It includes information about the meeting date, voting procedures, agenda items including the 2023 financial report, annual report, board work report, and other proposals to be voted on. It also contains instructions for shareholders on how to register and vote, including proxy voting. The document is not the actual annual report or financial statements but a notice about the AGM and the matters to be discussed and voted on at the meeting. The length is 4243 characters, which is relatively short and consistent with an AGM notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2024-04-19 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "海思科医药集团股份有限公司2024 年第一季度报告" which translates to "Haisco Pharmaceutical Group Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the first quarter of 2024. The document explicitly states it is a quarterly report and is unaudited. The length of the document (12,975 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-19 Chinese
独立董事2023年度述职报告（YAN JONATHAN JUN）
Board/Management Information Classification · 95% confidence The document is an independent director's annual performance report for the year 2023, detailing attendance at board meetings, independent opinions on various board matters, committee work, and compliance with relevant laws and regulations. It is a detailed report on the director's duties and activities rather than a general company annual report or financial statement. It does not contain financial data or audit results but focuses on board/management information and governance-related activities. Therefore, it fits best under Board/Management Information (MANG). The document length is 2424 characters, which is consistent with a detailed report but not a full annual report or audit report.
2024-04-19 Chinese
独立董事2023年度述职报告（乐军）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of the company, describing their duties, attendance at meetings, opinions on board matters, committee work, investor protection efforts, on-site work, and training during the year 2023. It is a formal report on the independent director's activities and responsibilities over the year, not an announcement or a brief notice. The content aligns with a Management Report or detailed governance-related reporting. However, since it focuses on the independent director's annual work report, it fits best under Board/Management Information (MANG), which covers announcements related to board members and senior management activities. The document is 3072 characters, which is substantial for a report of this nature but not a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2024-04-19 Chinese
关于2023年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2023 annual profit distribution plan of the company. It details the proposed cash dividend per share, the total dividend amount, and the approval process by the board and supervisory committee. It does not contain full financial statements or comprehensive financial performance data but rather focuses on the dividend proposal and related approvals. The document length is 1843 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2024-04-19 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.